Homburger with ADC Therapeutics on financing agreement amendment
Homburger advised ADC Therapeutics in connection with the amendment of its royalty purchase agreement with entities managed by HealthCare Royalty.
As consideration for reducing change of control payment from USD 750 m to USD 150 m to USD 200 m, HealthCare Royalty has received warrants to purchase approximately 9.8 m common shares of ADC Therapeutics at an exercise price of USD 3.81 per share.
The Homburger team
Daniel Häusermann (pictured) led the Homburger team on the matter, working alongside Estelle Piccard and Anina Preusker (all corporate/M&A, capital markets).
